Autoimmune Conditions

  • A $10 million gift has enabled the launch of a center focusing on optic disc drusen, a poorly understood eye disease that can lead to visual impairment or even blindness.

  • Microbial loss, ulcerative colitis linked

    Bacteria normally inhabiting healthy people’s intestines — and the anti-inflammatory metabolites these bacteria produce — are depleted in ulcerative colitis patients, a Stanford study shows.

  • Stanford-led teams nab top clinical research prizes

    Winning studies were chosen by members of the Clinical Research Forum, a nonprofit foundation that promotes the understanding of clinical research and its impact on health and health care.

  • New incubator for life science innovation

    A recently vacated building in Stanford Research Park will be the future home of a new life science incubator and lab suites. Located near campus, this incubator will serve as an anchor for a preeminent life science district.

  • Inflammation turns mutation deadly

    A simple viral infection in the lungs of rats can become a lethal form of pulmonary hypertension if a common mutation is present, new Stanford research shows.

  • Success in rheumatoid arthritis trial

    In a large trial led by a Stanford investigator, an experimental drug produced clinically meaningful improvements for rheumatoid arthritis patients unresponsive to existing treatments.

  • Possible drug target for cardiomyopathy

    Stanford researchers have uncovered how a genetic mutation contributes to a heart disease known as familial dilated cardiomyopathy. Existing drugs correct the defect in heart cells grown in a petri dish, suggesting a new therapeutic target.

  • Chronic fatigue syndrome biomarker found

    Stanford scientists devised a blood-based test that accurately identified people with chronic fatigue syndrome, a new study reports.

  • Drug reduces kidney failure in diabetics

    Canagliflozin, a drug approved to lower glucose levels in diabetic patients, can slow the progression of kidney disease, according to a study co-authored by a Stanford Medicine researcher.

  • Possible ‘bubble boy’ disease therapy

    In preclinical trials, Stanford scientists and their collaborators harnessed the gene-editing system CRISPR-Cas9 to replace the mutated gene underpinning the devastating immune disease.

  • Possible zinc strategy for diabetes

    To treat diabetes directly, rather than manage its symptoms, doctors need a way to get drugs to cells that produce insulin. The key, Stanford researchers report, may be those cells’ affinity for zinc.

  • Glucose spikes seen in healthy people

    A study out of Stanford in which blood sugar levels were continuously monitored reveals that even people who think they’re “healthy” should pay attention to what they eat.